Drug Profile
Research programme: Canavan disease therapeutics - Vyera Pharmaceuticals
Alternative Names: TUR-007Latest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator Turing Pharmaceuticals
- Developer Vyera Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Canavan disease
Most Recent Events
- 25 Aug 2023 Discontinued - Preclinical for Canavan disease in USA (unspecified route) before August 2023
- 28 Aug 2019 No recent reports of development identified for preclinical development in Canavan disease in USA
- 01 Sep 2017 Turing Pharmaceuticals is now called Vyera Pharmaceuticals